Localised prostate cancer at high risk of recurrence research hub

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD

This study is looking at how a new treatment for prostate cancer, called enzalutamide, works when used with standard hormone therapy and radiation. It's for men with prostate cancer that hasn't spread but is considered high-risk. We want to see if this combination stops the cancer from spreading.